<DOC>
	<DOCNO>NCT01471704</DOCNO>
	<brief_summary>The purpose study evaluate potential pharmacokinetic ( PK ) drug-drug interaction INX-08189 extend release verapamil hydrochloride ( verapamil HCL ER ) .</brief_summary>
	<brief_title>Study Investigating Pharmacokinetic Interaction Between INX-08189 Verapamil HCL ER Healthy Volunteers</brief_title>
	<detailed_description>This single-center , open-label , single-sequence , crossover , drug-drug interaction study healthy subject . Primary Objectives : Safety - To evaluate safety single dose INX-08189 ( 50 mg ) alone combine verapamil HCL ER ( 240 mg ) subject receive verapamil HCL ER QD 6 day Pharmacokinetic - To evaluate effect multiple dos verapamil HCL ER ( 240 mg ) pharmacokinetic ( PK ) profile INX-08189 metabolite INX-08032 , effect single dose INX-08189 PK profile verapamil metabolite norverapamil</detailed_description>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Subjects must meet follow criterion screen visit ( Visit1 ) Visit 2 order eligible study drug administration : 1 . Must healthy male female 18 55 year age ( inclusive ) body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) , weigh &gt; 50 kg time sign informed consent ; 2 . Capable give write informed consent include compliance requirement restriction list consent form . Signed informed consent must file prior screening procedure ; 3 . Subject able understand comply protocol requirement , instruction restriction ; 4 . Must nontobacco user least 3 month prior selection ; 5 . Healthy basis physical examination , medical history , vital sign , electrocardiogram clinical laboratory test screen ; 6 . Women must postmenopausal least 2 year surgically sterile complete hysterectomy bilateral oophorectomy , pregnant breastfeeding ; 7 . Male subject , surgically sterile vasectomy , must agree use double barrier method birth control , , condom plus spermicidal agent ( foam/gel/film/cream/suppository ) . This criterion must follow time first dose study medication 30 day last dose medication . Male subject donate sperm study 3 month receive last dose study drug . Subjects must NOT meet follow criterion Screening Visit ( Visit1 ) , order eligible study drug administration Visit 2 : 1 . Infection Hepatitis A , B C Virus ; 2 . Infection Human Immunodeficiency Virus ( HIV ) ; 3 . History current medical condition could impact safety participant study ; 4 . Current active underlying GI , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease ; 5 . Clinically significant abnormality centrally read ECG include evidence bradycardia ( rate &lt; 60 bpm ) evidence PR prolongation ; 6 . Screening vital sign represent heart rate &lt; 60 bpm , systolic blood pressure &lt; 90 mm Hg , diastolic blood pressure &lt; 60 mm Hg ; 7 . Currently significant diarrhea , gastric stasis , constipation investigator 's opinion could influence drug absorption bioavailability ; 8 . Safety laboratory abnormality screen clinically significant , absolute neutrophil count &lt; 1800 cells/mm3 , platelet count &lt; 130,000 cells/mm3 , hemoglobin &lt; 12 g/dl woman &lt; 13 g/dl men ; 9 . Women child bear potential , pregnant breastfeeding ; 10 . Current abuse alcohol illicit drug , history alcohol illicit drug abuse within precede 2 year ; 11 . A positive urine drug test screening ; 12 . Consumption 2 unit alcoholic beverage per day 14 unit per week ( 1 unit alcohol equal 1 glass beer , 1 glass wine , 25ml shot 40 % spirit ) , consumption alcohol 72 hour study medication intake , consumption average five ( 5 ) 240 ml serving coffee caffeinated beverage per day ; 13 . Use chronic prescription medication within 3 month , acute prescription medication within 14 day , systemic overthecounter ( OTC ) medication , include vitamin , within 7 day start study ; 14 . Received investigational drug vaccine use investigational medical device within 3 month 5 half life ( whichever longer ) plan start treatment participate previously study INX08189 ; 15 . Subjects use drug substance know inhibit induce cytochrome ( CYP ) P450 enzymes and/or Pglycoprotein ( Pgp ) within 28 day prior first dose throughout study ; 16 . Consumption grapefruit grapefruit juice start 48 hour Study Day 1 , subject 's confinement unit , outpatient followup period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>PK</keyword>
	<keyword>INX08189</keyword>
	<keyword>Verapamil</keyword>
	<keyword>Inhibitex</keyword>
</DOC>